| Literature DB >> 25807559 |
Francesca Chianini1, Gian Mario Cosseddu2, Philip Steele1, Scott Hamilton1, Jeremy Hawthorn3, Sílvia Síso4, Yvonne Pang1, Jeanie Finlayson1, Samantha L Eaton1, Hugh W Reid1, Mark P Dagleish1, Michele Angelo Di Bari2, Claudia D'Agostino2, Umberto Agrimi2, Linda Terry3, Romolo Nonno2.
Abstract
The transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of fatal neurodegenerative disorders characterised by the accumulation of a pathological form of a host protein known as prion protein (PrP). The validation of abnormal PrP detection techniques is fundamental to allow the use of high-throughput laboratory based tests, avoiding the limitations of bioassays. We used scrapie, a prototype TSE, to examine the relationship between infectivity and laboratory based diagnostic tools. The data may help to optimise strategies to prevent exposure of humans to small ruminant TSE material via the food chain. Abnormal PrP distribution/accumulation was assessed by immunohistochemistry (IHC), Western blot (WB) and ELISA in samples from four animals. In addition, infectivity was detected using a sensitive bank vole bioassay with selected samples from two of the four sheep and protein misfolding cyclic amplification using bank vole brain as substrate (vPMCA) was also carried out in selected samples from one animal. Lymph nodes, oculomotor muscles, sciatic nerve and kidney were positive by IHC, WB and ELISA, although at levels 100-1000 fold lower than the brain, and contained detectable infectivity by bioassay. Tissues not infectious by bioassay were also negative by all laboratory tests including PMCA. Although discrepancies were observed in tissues with very low levels of abnormal PrP, there was an overall good correlation between IHC, WB, ELISA and bioassay results. Most importantly, there was a good correlation between the detection of abnormal PrP in tissues using laboratory tests and the levels of infectivity even when the titre was low. These findings provide useful information for risk modellers and represent a first step toward the validation of laboratory tests used to quantify prion infectivity, which would greatly aid TSE risk assessment policies.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25807559 PMCID: PMC4373927 DOI: 10.1371/journal.pone.0122785
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Proportion of sheep testing PrPSc positive in each tissue by three Western blot methods.
| BioRad | Centrifuge | NaPTA | |
|---|---|---|---|
| no. positive/ no. tested | no. positive/ no. tested | no. positive/ no. tested | |
|
| 4/4 | 4/4 | 4/4 |
|
| 4/4 (49) | 4/4 (23) | 4/4 (30) |
|
| 4/4 (44) | 4/4 (19) | 4/4 (18) |
|
| 3/4 (5) | 3/4 (7) | 2/4 (3) |
|
| 1/4 (15) | 3/4 (12) | 1/4 (7) |
|
| 2/4 (12) | 1/4 (9) | 1/4 (5) |
|
| neg | neg | neg |
|
| neg | neg | neg |
|
| neg | neg | neg |
|
| neg | neg | neg |
|
| neg | neg | neg |
|
| neg | neg | neg |
Number in parentheses is the mean relative intensity (%) compared with 1/8 diluted brain sample.
Fig 1Different levels of abnormal PrP immunolabelling in selected tissues from scrapie positive sheep using R145 as primary antibody and Mayer’s haematoxylin as counterstain.
A: Widespread abnormal PrP labelling in the adrenal gland from B1216 (original magnification ×20). B: Abnormal PrP in the secondary follicles of the prescapular lymph node from B1217 (original magnification ×10). C: Widespread distribution of Abnormal PrP in the obex from B1217 (original magnification ×10). D: Very localised deposition of Abnormal PrP in the spindles of the semitendinous muscle from B1216 (original magnification ×40). E and F: examples of different level of deposition of PrPd in the renal papillae from respectively B1223 and B1217 (original magnification E ×20 and F×40).
Fig 2Relative intensity of chemiluminescent signal of PrPSc in tissues from 4 ARQ/ARQ sheep measured from Western blot image data (see adjacent panel) of edible tissues compared with a 12.5% dilution of brain sample by three western blot methods.
(a) BioRad TeSeE Western Blot, (b) centrifugal concentration, (c) NaPTA precipitation. Red diamonds indicate high signal; yellow – low signal; blue – negative.
ELISA results.
| Tissue | Sheep Number | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| B1221 | B1217 | N523 | ||||||
| BR | Idexx | BR | Idexx | BR | Idexx | BR | Idexx | BR | Idexx | |
|
|
|
|
|
|
|
|
|
| 0.006 | 0.018 |
|
|
|
|
|
|
|
|
|
| 0.004 | 0.045 |
|
| 0.009 |
| 0.007 |
| 0.011 | 0.049 | 0.008 |
| 0.002 | 0.041 |
|
|
| 0.044 |
|
|
| 0.050 |
| 0.047 | 0.016 | 0.030 |
|
|
| 0.048 |
|
| nd | 0.042 |
| 0.059 | 0.015 | 0.063 |
|
|
|
|
| 0.094 | 0.006 |
|
|
| 0.005 | 0.031 |
|
| 0.025 | 0.041 | 0.021 | 0.044 | 0.018 | 0.045 |
| 0.032 | 0.013 | 0.035 |
|
| 0.007 | 0.061 | 0.014 | 0.049 | 0.021 | 0.042 | 0.013 | 0.039 | 0.008 | 0.038 |
|
| 0.022 | 0.054 | 0.015 | 0.058 | 0.027 | 0.050 | 0.014 | 0.053 | 0.015 | 0.044 |
|
| 0.024 | 0.050 | 0.015 | 0.060 | nd | 0.044 | 0.015 | 0.050 | 0.011 | 0.045 |
Detection of PrPSc in target tissues from four scrapie-infected ARQ/ARQ, MRI sourced, Suffolk sheep (B1216, B1223, B1221, B1217B) and an unexposed ARQ/ARQ sheep (N523) using modified Bio-Rad TeSeE sheep and goat ELISA (BR) and the Idexx Herd-Chek scrapie antigen assay (Idexx). Values in bold are greater than the experimental cut-off values for each tissue. Tissues from the sheep underlined were inoculated into bank voles to determine infectivity. The numbers represent the absorbance values (450–620 nm). Each tissue was assayed at least twice and the results shown are values for assays completed in parallel on the same day.
Nd represents not done.
* In a repeat assay the value for this tissue fell below the cut-off value.
Relative quantity of PrPSc in edible tissues as measured by end-point dilution using the Idexx HerdChek antigen assay.
| Tissue | Sheep Number | |||
|---|---|---|---|---|
| B1216 | B1223 | B1221 | B1217 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| nd | 1/16 |
|
| nd |
| nd | nd |
|
| nd |
| nd | nd |
|
|
| nd |
|
|
The values shown are the final dilution where a positive signal was observed. Nd represents not done as these tissues were negative.
Bioassay of edible tissues in voles.
| Sheep ID | Tissue | Clinically + WB + N (surv. t. range) | Clinically—WB + N (surv. t. range) | Clinically—WB—N (surv. t. range) | Survivors | Attack rate |
|---|---|---|---|---|---|---|
| B1223 | Sciatic Nerve | 6 (218–554) | 1 (487) | 6 (280–600) | 2 (835) | 7/15 |
| B1216 | Sciatic Nerve | 5 (236–697) | 2 (309; 561) | 6 (211–656) | 7 (735) | 7/20 |
| B1223 | Prescap. LN | 11 (189–475) | 2 (250–369) | 4 (202–657) | 0 | 13/17 |
| B1216 | Prescap. LN | 8 (242–463) | 2 (277; 281) | 3 (298–551) | 1 (805) | 10/14 |
| B1223 | Kidney | 1 (466) | 0 | 10 (204–700) | 6 (785) | 1/17 |
| B1216 | Kidney | 1 (652) | 1 (670) | 9 (461–767) | 8 (789) | 2/19 |
| B1223 | Oculomotor Ms | 6 (328–405) | 0 | 6 (340–747) | 3 (833) | 6/15 |
| B1216 | Oculomotor Ms | 1 (204) | 0 | 10 (228–788) | 6 (830) | 1/17 |
| B1223 | Semitend. Ms | 0 | 0 | 12 (202–719) | 4 (805) | 0/16 |
| B1216 | Semitend. Ms | 0 | 0 | 10 (369–699) | 8 (789) | 0/18 |
| B1223 | Heart | 0 | 0 | 10 (375–771) | 7 (805) | 0/17 |
| B1216 | Heart | 0 | 0 | 9 (391–645) | 4 (805) | 0/13 |
| B1223 | Tongue | 0 | 0 | 6 (347–789) | 5 (830) | 0/11 |
| B1216 | Tongue | 0 | 0 | 5 (211–571) | 5 (831) | 0/10 |
* Clinically healthy voles culled at the end of the experiment.
Attack rates and survival times in voles inoculated with edible tissues from scrapie affected sheep in comparison to brain endpoint dilutions.
| Sheep B1223 | Sheep B1216 | |||
|---|---|---|---|---|
| Attack rate (%) | Survival time mean (SD) | Attack rate (%) | Survival time mean (SD) | |
| Tissues | ||||
| Brain−1 | 100% | 187 (13) | 100% | 176 (13) |
| Brain−2 | 100% | 225 (93) | 100% | 212 (39) |
| Brain−3 | 92% | 351 (93) | 73% | 278 (46) |
| Brain−4 | 23% | 403 (154) | 8% | 216 |
| Brain−5 | 0% | 0% | ||
| Brain−6 | 0% | 0% | ||
| Sciatic Nerve | 47% | 339 (153) | 35% | 411 (168) |
| Tongue | 0% | 0% | ||
| Prescap. LN | 76% | 276 (80) | 71% | 317 (71) |
| Heart | 0% | 0% | ||
| Kidney | 6% | 456 | 11% | 652–670 |
| Semitend. Ms | 0% | 0% | ||
| Oculomotor Ms | 40% | 376 (28) | 6% | 204 |
* the survival time of the only positive vole is reported
** the survival times of the two positive voles are reported
Comparison of PrPSc, infectivity and converting activity by PMCA in the inocula.
| Sheep B1223 | Sheep B1216 | ||||
|---|---|---|---|---|---|
| WB | Bioassay | WB | Bioassay | PMCA | |
| Brain −1 |
|
|
|
|
|
| Brain −2 |
|
|
|
|
|
| Brain −3 |
|
|
|
|
|
| Brain −4 | neg |
| neg |
|
|
| Brain −5 | neg | neg | neg | neg |
|
| Brain −6 | neg | neg | neg | neg | neg |
| Sciatic Nerve |
|
|
|
|
|
| Tongue | − | − | − | − | neg |
| Prescap. LN |
|
|
|
|
|
| Heart | − | − | − | − | neg |
| Kidney |
|
| − |
|
|
| Semitend. Ms | − | − | − | − | neg |
| Oculomotor Ms |
|
|
|
|
|
* For the brain dilutions, only positive and negative dilutions are indicated. For the edible tissues a semi-quantification is provided. The WB signal was semi-quantified as follows:
+++ = a tissue positive in all experiments and with a WB signal between brain dilutions −2 and −3
++ = a tissue positive in at least 2/3 experiments and with a WB signal similar to brain dilution −3 or less
+/− = a tissue positive in 1/3 experiments and with a WB signal below brain dilution −3
** For the brain dilutions, only positive and negative dilutions are indicated. For the edible tissues a semi-quantification is provided. The bioassay results were categorised as follows (see Table 5 and S2 Fig.)
+++ = similar to brain dilution −3 or more efficient
++ = between brain dilutions −3 and −4
+ = similar to brain dilution −4 or less efficient
Summary of the IHC, WB, ELISA and bioassay results.
| Scrapie 1 (B1216) | Scrapie 2 (B1223) | Scrapie 3 (B1221) | Scrapie 4 (B1217) | Negative Control (N523) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tissues | IHC | WB | E | VB | IHC | WB | E | VB | IHC | WB | E | VB | IHC | WB | E | VB | IHC | WB | E | VB |
|
| +++ | +/+/+ | +/+ | pos | +++ | +/+/+ | +/+ | pos | +++ | +/+/+ | +/+ | nd | +++ | +/+/+ | +/+ | nd | − | − /− /− | −/− | nd |
|
| +++ | +/+/+ | nd | nd | +++ | +/+/+ | nd | nd | +++ | +/+/+ | nd | nd | +++ | +/+/+ | nd | nd | − | − /− /− | nd | nd |
|
| +++ | +/nd/+ | +/+ | +++ | +++ | +/+/+ | +/+ | +++ | +++ | +/+/+ | +/+ | nd | +++ | +/+/+ | +/+ | nd | − | − /− /− | −/− | nd |
|
| +++ | +/+/+ | +/+ | + | +++ | +/+/− | +/− | ++ | +++ | − /− /− | −/+ | nd | +++ | +/+/+ | +/+ | nd | − | − /− /− | −/− | nd |
|
| + | −/+/− | −/+ | ++ | + | +/+/− | −/+ | ++ | + | −/−/nd | −/− | nd | ++ | −/+/+ | −/+ | nd | − | − /− /− | −/− | nd |
|
| − | − /− /− | +/− | + | +++ | +/+/+ | +/+ | + | − | +/−/− | +/− | nd | ++ | − /− /− | +/− | nd | − | − /− /− | −/− | nd |
|
| ++ | − /− /− | −/− | − | − | −/− /− | −/− | − | − | − /− /− | −/− | nd | − | − /− /− | − | nd | − | − /− /− | −/− | nd |
|
| +++ | − /− /− | nd | nd | − | − /− /− | nd | Nd | − | − /− /− | nd | nd | ++ | − /− /− | nd | nd | − | − /− /− | nd | nd |
|
| − | − /− /− | −/− | − | − | − /− /− | −/− | − | − | − /− /− | −/− | nd | − | − /− /− | +/− | nd | − | − /− /− | −/− | nd |
|
| − | − /− /− | −/− | − | − | − /− /− | −/− | − | − | − /− /− | −/− | nd | − | − /− /− | −/− | nd | − | − /− /− | −/− | nd |
|
| − | − /− /− | −/− | nd | − | − /− /− | −/− | nd | − | − /− /− | −/− | nd | − | − /− /− | −/− | nd | − | − /− /− | −/− | nd |
|
| − | − /− /− | nd | nd | − | − /− /− | nd | nd | − | − /− /− | nd | nd | − | − /− /− | nd | nd | − | − /− /− | nd | nd |
IHC: Score denotes the abundance of PrPd in each visceral tissue; no labelling (−), mild (+), moderate(++) or severe accumulation (+++) of PrPd. For muscle samples a semi-quantitative scoring system was applied to no. of positively labelled spindles; 0 (−), 1 (+), 1–5 (++), >5 (+++)
WB: +1/ +2/ +3 denotes pos/neg results from three separate methods where 1 = BioRad; 2 = centrifugal concentration; 3 = NaPTA
E = ELISA: +1/ +2 denotes pos/neg results from two separate methods where 1 = BioRad; 2 = IDEXX
VB = Vole bioassay results were categorised as follows (+++) = similar to brain dilution-3 or more efficient,
(++) = between brain dilutions −3 and −4, (+) = similar to brain dilution −4 or less efficient
Fig 3Converting activity in the inocula from 1216B sheep analysed by vPMCA.
Western blot analysis of the amplified products was carried out after the 3rd, 5th, 7th and 9th rounds, as indicated. The results obtained with the brain dilution curve are reported in left panels, those from visceral tissue inocula are in right panels. Blots were probed with SAF84 primary antibody.